Adrenaline with articaine hydrochloride
Brand names: Septanest
A dental local anaesthetic injection combining articaine, an amide local anaesthetic, with adrenaline as a vasoconstrictor, used for infiltration and nerve-block anaesthesia in dentistry.
Adult dose
Paediatric dose
Dose adjustments
No numerical renal dose adjustment is printed. §4.2: 'Due to the lack of clinical data, particular precaution should be used in order to administer the lowest dose leading to effective anaesthesia in elderly patients and in patients with renal disorders (section 4.4 and 5.2). Elevated product plasma levels may occur in these patients in particular after repeated use. In case of required reinjection, patient should be strictly monitored, to identity any sign of relative overdose (see section 4.9).' §4.4: patients with renal disease, the lowest dose leading to effective anaesthesia should be used.
No numerical hepatic dose adjustment is printed. §4.2: 'Particular precaution should be used in order to administer the lowest dose leading to efficient anaesthesia in patients with hepatic impairment, in particular after repeated use, although 90% of articaine is first inactivated by unspecific plasma esterases in the tissue and blood.' §4.4: in severe hepatic disease the product should be used cautiously.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to articaine (or any local anaesthetic agent of the amide type), to adrenaline or to any of the excipients listed in section 6.1 (§4.3)
- Patients with epilepsy not controlled by treatment (§4.3)
Side effects
- Adverse reactions are similar to those observed with other local amide anaesthetics / vasoconstrictors and are, in general, dose-related; they may also result from hypersensitivity, idiosyncrasy or diminished tolerance. Nervous system disorders, local injection site reaction, hypersensitivity, cardiac disorders and vascular disorders are the most frequently occurring; serious adverse reactions are generally systemic (§4.8)
- Common (as read in the extracted table): gingivitis; neuropathy including neuralgia (neuropathic pain), hypoesthesia / numbness (oral and perioral), hyperesthesia, dysesthesia (oral and perioral) including dysgeusia (e.g. taste metallic, taste disturbance), ageusia, allodynia, thermohyperesthesia; headache; bradycardia; tachycardia; hypotension (with possible circulatory collapse); swelling of tongue, lip, gums (§4.8)
- Uncommon (as read): burning sensation; hypertension; stomatitis, glossitis; nausea, vomiting, diarrhoea; rash (eruption), pruritus; neck pain (§4.8)
- Rare (as read): allergic, anaphylactic / anaphylactoid reactions; nervousness / anxiety; facial nerve disorder (palsy, paralysis and paresis); Horner's syndrome (eyelid ptosis, enophthalmos, miosis); somnolence (drowsiness); nystagmus; diplopia (paralysis of oculomotor muscles); visual impairment (temporary blindness); ptosis; miosis; enophthalmos; hyperacusis; tinnitus; palpitations; hot flush; bronchospasm / asthma; dyspnoea; gingival / oral mucosal exfoliation (sloughing) / ulceration; angioedema (face / tongue / lip / throat / larynx / periorbital oedema); urticaria; muscle twitching (§4.8)
- Very rare (as read): paresthesia (persistent hypoesthesia and gustatory loss) after mandibular or inferior alveolar nerve blocks (§4.8)
- Not known (as read): euphoric mood; conduction disorders (atrioventricular block); local / regional hyperaemia; vasodilatation; vasoconstriction; dysphonia (hoarseness); dysphagia; swelling of cheeks; glossodynia; erythema; hyperhidrosis; aggravation of the neuromuscular manifestations (text cut off) (§4.8)
- The extracted §4.8 table lost its column layout and footnote markers, and the section is cut at the source-fetch limit, so the frequency-to-term pairing above should be checked against the SPC and the list is partial
- Adrenaline impairs the flow of blood in the gums, potentially causing local tissue necrosis; very rare cases of prolonged or irreversible nerve injury and gustatory loss have been reported after mandibular block analgesia (§4.4)
- Sodium metabisulfite (excipient) may rarely cause hypersensitivity reactions and bronchospasm (§4.4)
- Risk of biting trauma (lips, cheeks, mucosa and tongue), especially in children; the patient should avoid chewing gum or eating until normal sensation is restored (§4.4)
Interactions
- Other local anaesthetics: toxicity is additive; the total dose of all local anaesthetics administered should not exceed the maximum recommended dose of the drugs used (§4.5)
- Sedatives (CNS depressants, e.g. benzodiazepines, opioids): additive CNS depression; use reduced doses of anaesthetic (§4.5, §4.2)
- Halogenated volatile anaesthetics (e.g. halothane): use reduced doses because of sensitisation of the heart to the arrhythmogenic effects of catecholamines (risk of severe ventricular arrhythmia); discuss with the anaesthetist before local anaesthetic administration during general anaesthesia (§4.5)
- Postganglionic adrenergic blocking agents (e.g. guanadrel, guanethidine, rauwolfia alkaloids): use reduced doses under strict medical supervision with careful aspiration; risk of hypertension and other cardiovascular effects (§4.5)
- Non-selective beta-adrenergic blockers (e.g. propranolol, nadolol): use reduced doses; possible increase in blood pressure and increased risk of bradycardia (§4.5)
- Tricyclic antidepressants (e.g. amitriptyline, desipramine, imipramine, nortriptyline, maprotiline, protriptyline): reduce dose and rate of administration because of increased risk of severe hypertension (§4.5)
- COMT inhibitors (e.g. entacapone, tolcapone): arrhythmias, increased heart rate and blood pressure variations may occur; give a reduced amount of adrenaline (§4.5)
- MAO inhibitors (A-selective, e.g. moclobemide, and non-selective, e.g. phenelzine, tranylcypromine, linezolid): if concurrent use cannot be avoided, reduce dose and rate of administration and use under strict medical supervision because of the risk of hypertensive crisis (§4.5)
- Drugs causing arrhythmias (e.g. antiarrhythmics such as digitalis, quinidine): reduce the dose because of the increased risk of arrhythmia with adrenaline; careful aspiration prior to administration is recommended (§4.5)
- Ergot-type oxytocic drugs (e.g. methysergide, ergotamine, ergonovine): the retrieved §4.5 text is cut off at this entry and the advice was not retrieved
Monitoring
- Make inquiries into the patient's current therapies and history, maintain verbal contact with the patient and have resuscitative equipment at hand (§4.4)
- Monitor the patient's state of consciousness after each local anaesthetic injection (§4.2)
- Lowest effective dose in patients with cardiac impulse formation and conduction disturbances, acute decompensated heart failure, hypotension, paroxysmal tachycardia or absolute arrhythmias with rapid heart rate, unstable angina or myocardial infarction within 6 months, coronary artery bypass surgery within 3 months, non-cardioselective beta-blockers, uncontrolled hypertension, or concomitant tricyclic antidepressants; consider postponing dental surgery if the condition is severe and/or unstable (§4.4)
- Strictly monitor any patient who needs reinjection (elderly, renal disorder, cholinesterase deficiency) for signs of relative overdose (§4.2, §4.4)
- Plasma cholinesterase deficiency can be suspected when clinical signs of overdose occur with the usual dose and a vascular injection has been excluded; use a reduced dose for the next injection (§4.4)
- Consider the 1:200,000 product over 1:100,000 (adrenaline 5 micrograms/ml) in patients with cardiovascular disease, cerebral circulation disturbances or history of stroke; defer dental treatment with articaine/adrenaline for six months following a stroke; use cautiously in uncontrolled diabetes, thyreotoxicosis, phaeochromocytoma and susceptibility to acute angle-closure glaucoma (§4.4)
- Use with caution in patients taking antiplatelet / anticoagulant medicines or with coagulation disorders (higher risk of bleeding, more associated with the procedure than the medicine); use only in acute porphyria when no safer alternative is available (§4.4)
- Reduce the dose in hypoxia, hyperkalaemia and metabolic acidosis; the local anaesthetic effect may be reduced in inflamed or infected tissue (§4.4)
Clinical monograph
How it works
Articaine reversibly blocks voltage-gated sodium channels in nerve fibres to prevent impulse conduction, while the added adrenaline causes local vasoconstriction that prolongs anaesthesia and reduces systemic absorption of the local anaesthetic.
Prescribing in practice
- Avoid inadvertent intravascular injection, which can cause systemic local-anaesthetic and adrenaline toxicity; aspirate before injecting and use the lowest effective volume.
- The adrenaline component warrants caution in cardiovascular disease, hyperthyroidism and in patients taking tricyclic antidepressants or non-selective beta-blockers, where pressor effects may be exaggerated.
- Articaine is metabolised largely by plasma esterases; use cautiously where there is methaemoglobinaemia risk and follow the SPC for population-specific limits.
Monitoring
Observe the patient during and after injection for signs of systemic toxicity, vasovagal reactions or excessive cardiovascular stimulation.
Counselling the patient
- Numbness of the lips, tongue and cheek will persist for some time after the procedure, so avoid biting the area or taking hot drinks until sensation returns.
- Report palpitations, dizziness or feeling faint promptly.
Evidence & guidelines
Use is supported by established dental anaesthesia practice and the product SPC; articaine with adrenaline is a widely used dental local anaesthetic.
Reference: AAGBI Safety Guideline – Local Anaesthetic Toxicity 2010; SmPC Septanest; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.